Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $19.88M rose 61.2% year over year, ahead of the +16.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 42.1% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.

Context

  • Selling, general & admin amounted to 336.5% of revenue in FY2025.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 12 analysts of $8.77M (-82.6%) for the fiscal year ending Dec 2026, a slowdown from the -0.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.88M+42.1% QoQ
Last fiscal yearDec 2025
$50.47M-0.7% YoY
LTMMar 2026
$58.02M+16.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+61.2%-100.0%-161.2 pp
1 year-0.7%-82.6%-81.9 pp
3-year CAGR-2.9%+131.3%+134.3 pp
5-year CAGR+118.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
50.47M USD
Year-over-year change
-0.7%
4-year CAGR
+4.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CNTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +16.7% is the 7th highest of 10, against a peer median of +33.3%.
  • Over three fiscal years its annual growth of -2.9% compares with a peer median of +34.4%.
CNTA Competitors
Selling, General & Admin for CNTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥522.67M CNY+36.4%+16.8%93.6%
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M USD+10.5%+25.2%26.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$350.27M USD+5.7%+7.9%52.3%
ZLABZai Lab LimitedLTM Jun 2026$281.09M USD-1.1%+2.3%62.5%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$94.24M USD+24.7%+34.4%—
DYNDyne Therapeutics, Inc.LTM Jun 2026$91.25M USD+50.5%+35.3%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026$90.71M USD+34.9%+125.7%1471.2%
APGEApogee Therapeutics, Inc.LTM Jun 2026$83.07M USD+33.3%+188.9%—
CELCCelcuity Inc.LTM Jun 2026$71.99M USD+448.5%+83.8%—
CNTACentessa Pharmaceuticals plcLTM Mar 2026$58.02M USD+16.7%-2.9%—
Peer median (excluding CNTA) —+33.3%+34.4%62.5%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.